PATENT CLAIM ANALYSIS

Application Number: 15948594
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "300000"]

Abstract:
Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Claim (Index 1):
A compound of the Formula (I): wherein:\n m is an integer from 1 to 5; \n R\u2032 is selected from the group consisting of:\n hydroxy, \n thiol, \n \u2014S(O) 0-2 -alkyl, \n \u2014S(O) 2 \u2014NH\u2014R 9 , \n alkoxy, \n \u2014O\u2014C 1-3  alkylene-S(O) 2 -alkyl, \n \u2014N(R 9 ) 2 , and \n \u2014NH-Q-R 4 ; \n \n Z is selected from the group consisting of:\n a bond, \n C 1-5  alkylene, \n \n A\u2032 is selected from the group consisting of:\n \u2014O\u2014, \n \u2014C(O)\u2014, \n \u2014N(R 8 )\u2014, \n \u2014N(Q-R 4 )\u2014, \n \u2014N(C 1-5  alkylene-NH-Q-R 4 )\u2014, \n \u2014N(C 1-5  alkylene-W\u2014NH\u2014R 8 )\u2014, and \n \u2014S(O) 0-2 \u2014; \n R 2  is selected from the group consisting of:\n \u2014R 4 , \n \u2014X\u2014R 4 , \n \u2014X\u2014Y\u2014R 4 , and \n \u2014X\u2014R 5 ; \n when taken together, R A  and R B  form a fused heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the heteroaryl ring is unsubstituted or substituted by one or more R groups; or when taken together, R A  and R B  form a fused 5 to 7 membered saturated ring, containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;\n R is selected from the group consisting of:\n halogen, \n hydroxy, \n alkyl, \n alkenyl, \n haloalkyl, \n alkoxy, \n alkylthio, and \n \u2014N(R 9 ) 2 ; \n \n X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more \u2014O\u2014 groups; \n Y is selected from the group consisting of:\n \u2014S(O) 0-2 \u2014, \n \u2014S(O) 2 \u2014N(R 8 )\u2014, \n \u2014C(R 6 )\u2014, \n \u2014C(R 6 )\u2014O\u2014, \n \u2014O\u2014C(R 6 )\u2014, \n \u2014O\u2014C(O)\u2014O\u2014, \n \u2014N(R 8 )-Q-, \n \u2014C(R 6 )\u2014N(R 8 )\u2014, \n \u2014O\u2014C(R 6 )\u2014N(R 8 )\u2014, \n \u2014C(R 6 )\u2014N(OR 9 )\u2014, \n \n R 4  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, acetylamino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; R 5  is selected from the group consisting of: R 6  is selected from the group consisting of \u2550O and \u2550S; R 7  is C 2-7  alkylene; R 8  is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; R 9  is selected from the group consisting of hydrogen and alkyl; R 10  is C 3-8  alkylene; R 11  is selected from the group consisting of hydrogen, alkyl, halogen, and trifluoromethyl; R 12  is selected from the group consisting of hydrogen, alkyl, phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; A is selected from the group consisting of \u2014O\u2014, \u2014C(O)\u2014, \u2014S(O) 0-2 \u2014, \u2014CH 2 \u2014, and \u2014N(R 4 )\u2014; Q is selected from the group consisting of a bond, \u2014C(R 6 )\u2014, \u2014C(R 6 )\u2014C(R 6 ), \u2014S(O) 2 \u2014, \u2014C(R 6 )\u2014N(R 8 )\u2014W\u2014, \u2014S(O) 2 \u2014N(R 8 )\u2014, \u2014C(R 6 )\u2014O\u2014, and \u2014C(R 6 )\u2014N(OR 9 )\u2014; and V is selected from the group consisting of \u2014C(R 6 )\u2014, \u2014O\u2014C(R 6 )\u2014, \u2014N(R 8 )\u2014C(R 6 )\u2014, and \u2014S(O) 2 \u2014; W is selected from the group consisting of a bond, \u2014C(O)\u2014, and \u2014S(O) 2 \u2014; and a and b are independently integers from 1 to 6 with the proviso that a+b is \u22647; with the proviso that when Z is a bond or C 1-5  alkylene then R\u2032 is other than \u2014O\u2014C 1-3  alkylene-S(O) 2 -alkyl, and with the further proviso that when Z is a bond or C 1-5  and R 2  is \u2014X\u2014Y\u2014R 4  and Y is \u2014N(R 8 )-Q-, then Q is other than \u2014C(R 6 )\u2014N(R 8 )\u2014W\u2014; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.5098
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11570707', '12974459', '14684871', '14021197', '11570703']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9215454525305252
- 35 USC 102 Novelty (BERT): 0.7161401568279793
- Combined Prediction Score: 0.9010049229602706
- Mean Citation Score: 765.912062
- Max Citation Score: 796.35455
- Similarity Product: 782.8989088036092

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test